Navigation Links
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/2/2010

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 10:00 a.m. EST (7:00 a.m. PST).  The conference is being held at the Waldorf-Astoria Hotel in New York.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

Additionally, Dr. Worland will participate as a panelist on the BIO CEO & Investor Conference HCV Panel on Tuesday, February 9, 2010 at 12:00 p.m. EST (9:00 a.m. PST).

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through February 23, 2010.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for th
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
2. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
3. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
5. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
6. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... 15 Watermark Medical , Inc., a privately-held, ... market, has expanded the market reach of its Web-enabled ... three leading sleep solution providers in the U.S. and ... national provider of comprehensive sleep apnea services; Sleep ...
... Vista Partners announced today that it has updated ... Principal Analyst at Vista Partners stated, "Raptor is potentially ... a balanced pipeline of clinical and preclinical programs.  The ... programs and one Phase 3 trial with some indications ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... date of its industry-defining contract lifecycle management solution, as well as announced the ... to increase the speed and ease of contract management tasks as well as ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number of ... to market research compiled for the National Association of Dental Laboratories ( NADL ... Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists will ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... CITY)Research into how carbohydrates are converted into energy has ... treatment of a perplexing and potentially fatal neuromuscular disorder ... this study, the cause of this neuromuscular disorder was ... members who have the disorder, a team led by ...
... , THURSDAY, May 24 (HealthDay News) -- While fewer people ... of strokes has remained about the same, health officials report. ... nation,s so-called "stroke belt." According to the report on ... strokes dipped slightly from 2.7 percent to 2.6 percent during ...
... a new, higher-yield, two-step, less costly process that may ... material essential for making the mainstay drug for malaria. ... more than 1 million. The report on the process, ... implemented by drug companies, appears in ACS, journal ...
... most comprehensive analyses to date of the cost of robotic-assisted, ... this now-dominant surgical approach is significantly more costly than standard ... outcomes. The results of the study are available online and ... Urology . In one of the first studies ...
... The British Association for Psychopharmacology (BAP) has released ... abuse and addiction in the Journal of Psychopharmacology ... carefully researched the new, comprehensive guidelines, offering practitioners a ... their clinical decisions. The new BAP guidelines target ...
... May 22 (HealthDay News) -- New research suggests that ... anticholinergics -- such as ipratropium [Atrovent] -- could be ... irregular heartbeat. However, the increased risk was ... this finding raises concern because of the recent interest ...
Cached Medicine News:Health News:Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease 2Health News:Strokes More Common in Southern States: CDC 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:British experts update addiction treatment guidelines 2Health News:Asthma Meds May Be Linked to Irregular Heartbeat 2
... Markers have a unique squeezable barrel ... writing over wet prep solutions. Micro ... with optional rulers and sterile labels ... sterile, packaged individually in peel pouches. ...
Broad tip, gentian violet, sterile, disposable...
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
Medicine Products: